Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | LGALS3 | P17931 | 6/20 | 0.44 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.44 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.44 |
| ▸ | MDK | P21741 | 3/20 | 0.43 |
| ▸ | BDNF | P23560 | 3/20 | 0.43 |
| ▸ | PTN | P21246 | 2/20 | 0.43 |
| ▸ | CD69 | Q07108 | 1/20 | 0.41 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.41 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.41 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12952583 | 1.00 | MAPK1 (0.44) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL15274904 | 1.00 | MAPK1 (0.44) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL12213976 | 1.00 | MAPK1 (0.44) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL15215584 | 1.00 | MAPK1 (0.44) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL18254178 | 1.00 | MAPK1 (0.44) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL12085239 | 1.00 | MAPK1 (0.44) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL25121361 | 1.00 | MAPK1 (0.44) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL15082697 | 1.00 | MAPK1 (0.44) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL21374694 | 1.00 | MAPK1 (0.44) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL10157433 | 1.00 | MAPK1 (0.44) | MAPK1LGALS3LGALS8LGALS4MDK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216575-A1 | BIOPOLYMER SCAFFOLDS AND METHODS FOR PRODUCTION OR USE THEREOF | BIONOVA MEDICAL, INC. (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240024487-A1 | SELF-REPAIRING BIOMIMETIC LUBRICANTS AND METHODS OF MAKING AND USING SAME | DUKE UNIVERSITY | 2024-01-25 | — | — | US | disclosed |
| US-11834560-B2 | Water degradable film containing hyaluronic acid or salt thereof and polyphenol compounds | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-12-05 | — | — | US | disclosed |
| US-11795320-B2 | Grafted polymer and use thereof | BAUSCH + LOMB IRELAND LIMITED (IE) | 2023-10-24 | — | — | US | disclosed |
| US-20230270761-A1 | IMMUNOMODULATORY, ORAL MICROBIOME ALTERING AND TISSUE REGENERATIVE ORAL CARE COMPOSITIONS AND METHODS OF USE IN THE PREVENTION AND TREATMENT OF PERIODONTAL AND PERI-IMPLANT DISEASES | JANOSI FAIR KATALIN (US) | 2023-08-31 | — | — | US | disclosed |
| US-11732060-B2 | Crosslinked polymeric network and use thereof | BAUSCH & LOMB INCORPORATED (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230257485-A1 | GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2023-08-17 | — | — | US | disclosed |
| US-11673974-B2 | Glycophospholipid polymeric network and use thereof | BAUSCH & LOMB INCORPORATED (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230165780-A1 | CROSSLINKED MATERIALS | FOUNT BIO, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230126726-A1 | CROSSLINKED HYALURONIC ACID AND USE THEREOF | MEDYTOX INC. (KR) | 2023-04-27 | — | — | US | disclosed |
| US-20140294752-A1 | METHOD FOR NUCLEIC ACID DELIVERY USING HYALURONIC ACID | Research & Business Foundation Sungkyunkwan University (KR) | 2014-10-02 | — | — | US | disclosed |
| US-20130303480-A1 | SOFT TISSUE AUGMENTATION THREADS AND METHODS OF USE THEREOF | TAUTONA GROUP LP | 2013-11-14 | — | — | US | disclosed |
| US-20130274222-A1 | THREADS OF CROSS-LINKED HYALURONIC ACID AND METHODS OF PREPARATION AND USE THEREOF | TAUTONA GROUP LP | 2013-10-17 | — | — | US | disclosed |
| US-20130142731-A1 | THREADS OF CROSS-LINKED HYALURONIC ACID AND METHODS OF USE THEREOF | Tau Tona Group LP | 2013-06-06 | — | — | US | disclosed |
| US-20130122068-A1 | THREADS OF CROSS-LINKED HYALURONIC ACID AND METHODS OF USE THEREOF | TAUTONA GROUP LP (US) | 2013-05-16 | — | — | US | disclosed |
| US-8247493-B2 | Long acting formulation of biopharmaceutical | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2012-08-21 | — | — | US | disclosed |
| US-20120108536-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR INHIBITING INFLAMMATION | CHINA MEDICAL UNIVERSITY (TW) | 2012-05-03 | — | — | US | disclosed |
| US-20110144030-A1 | CONJUGATE OF HYALURONIC ACID FOR COSMETIC TREATMENT AND PREPARATION METHOD | RAMIS CASTELLTORT MARC | 2011-06-16 | — | — | US | disclosed |
| US-20110111477-A9 | LONG ACTING FORMULATION OF BIOPHARMACEUTICAL | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2011-05-12 | — | — | US | disclosed |
| US-20100261245-A1 | LONG ACTING FORMULATION OF BIOPHARMACEUTICAL | POSCO (KR) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673974-B2 | Glycophospholipid polymeric network and use thereof | ALG1, CSGALNACT1, FUT5 | MAPK1 3364/4885LGALS3 65/4885LGALS8 147/4885 |
| US-20130122068-A1 | THREADS OF CROSS-LINKED HYALURONIC ACID AND METHODS OF USE THEREOF | CUTA, DSG1, COL14A1 | MAPK1 2330/4885LGALS3 389/4885LGALS8 252/4885 |
| US-20130274222-A1 | THREADS OF CROSS-LINKED HYALURONIC ACID AND METHODS OF PREPARATION AND USE THEREOF | CUTA, DSG1, COL14A1 | MAPK1 2095/4885LGALS3 626/4885LGALS8 409/4885 |
| US-20240024487-A1 | SELF-REPAIRING BIOMIMETIC LUBRICANTS AND METHODS OF MAKING AND USING SAME | MUC1, OGG1, DSG1 | MAPK1 4665/4885LGALS3 304/4885LGALS8 556/4885 |
| US-20100261245-A1 | LONG ACTING FORMULATION OF BIOPHARMACEUTICAL | VEGFA, CD44, HACD3 | MAPK1 3631/4885LGALS3 653/4885LGALS8 519/4885 |
| US-20140294752-A1 | METHOD FOR NUCLEIC ACID DELIVERY USING HYALURONIC ACID | CD44, DNASE1, HNRNPH3 | MAPK1 3782/4885LGALS3 1448/4885LGALS8 1262/4885 |
| US-11732060-B2 | Crosslinked polymeric network and use thereof | ALG1, CSGALNACT1, CD44 | MAPK1 4105/4885LGALS3 138/4885LGALS8 185/4885 |
| US-20230165780-A1 | CROSSLINKED MATERIALS | DCLRE1A, COL2A1, MTCL3 | MAPK1 4805/4885LGALS3 1263/4885LGALS8 996/4885 |
| US-20120108536-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR INHIBITING INFLAMMATION | HMGCR, HMGB2, HMGB3 | MAPK1 2795/4885LGALS3 406/4885LGALS8 826/4885 |
| US-20230270761-A1 | IMMUNOMODULATORY, ORAL MICROBIOME ALTERING AND TISSUE REGENERATIVE ORAL CARE COMPOSITIONS AND METHODS OF USE IN THE PREVENTION AND TREATMENT OF PERIODONTAL AND PERI-IMPLANT DISEASES | AHCY, CD44, TIMCC | MAPK1 2827/4885LGALS3 605/4885LGALS8 2027/4885 |
| US-20110111477-A9 | LONG ACTING FORMULATION OF BIOPHARMACEUTICAL | VEGFA, CD44, HACD3 | MAPK1 3631/4885LGALS3 653/4885LGALS8 519/4885 |
| US-20230257485-A1 | GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF | ALG1, CSGALNACT1, FUT6 | MAPK1 2507/4885LGALS3 58/4885LGALS8 126/4885 |
| US-20230126726-A1 | CROSSLINKED HYALURONIC ACID AND USE THEREOF | CD44, COL2A1, COL14A1 | MAPK1 4322/4885LGALS3 275/4885LGALS8 294/4885 |
| US-20110144030-A1 | CONJUGATE OF HYALURONIC ACID FOR COSMETIC TREATMENT AND PREPARATION METHOD | CD44, CUTA, MUC1 | MAPK1 2920/4885LGALS3 90/4885LGALS8 104/4885 |
| US-20130142731-A1 | THREADS OF CROSS-LINKED HYALURONIC ACID AND METHODS OF USE THEREOF | CUTA, DSG1, MMP1 | MAPK1 1987/4885LGALS3 456/4885LGALS8 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.